🏆 Deal of the Week · KW 18/2025
SafeHeal raised EUR 35 million in a Series C equity financing round, closed in April 2025; the company's valuation was not disclosed. The round was oversubscribed and backed by Solar Eclipse, Sofinnova Partners, M&L Healthcare Investments, and Gideon Strategic Partners.
SafeHeal — key deal facts
| Company | SafeHeal |
| Founded | 2015 |
| Headquarters | Paris, France |
| Amount raised | EUR 35M |
| Valuation | Valuation Remains Undisclosed |
| Round | Series C |
| Investors | Solar Eclipse, Sofinnova Partners, M&L Healthcare Investments, Gideon Strategic Partners |
| Sectors | Health Care |
Who invested in SafeHeal?
The syndicate combines transatlantic expertise: Sofinnova Partners is a specialist European life-sciences venture firm, while Solar Eclipse, M&L Healthcare Investments, and Gideon Strategic Partners add further strategic and institutional depth. The oversubscribed nature of the round signals strong investor conviction in SafeHeal's clinical and commercial trajectory. No single lead investor was publicly designated, yet the breadth of the group reflects cross-border confidence in the colorectal-device segment.
What does SafeHeal do?
SafeHeal is a clinical-stage medical device company founded in 2015 and headquartered in Paris, France. The company develops anastomosis protection devices for colorectal surgery, with its primary product being Colovac — a flexible endoluminal bypass sheath that protects the anastomotic site from fecal contact following colorectal cancer resection. Colovac remains in place for 7–10 days and is removed endoscopically, eliminating the need for a temporary diverting ostomy and the associated reversal surgery. The device was originally invented by French surgeon Dr. Khosrovani; the company is currently led by CEO Chris Richardson.
SafeHeal valuation & multiples
No existing multiples analysis was provided for this transaction. Because SafeHeal's post-money valuation remains undisclosed, EV/Sales and EV/EBITDA benchmarking cannot be applied directly to this deal. Readers seeking sector context can explore Venionaire DealMatrix's Health Care and Medical Devices multiples pages for comparable transaction ranges.
Explore the benchmarks: Series C.
Frequently asked questions
How much did SafeHeal raise in its Series C?
SafeHeal raised EUR 35 million in an oversubscribed Series C equity financing round that closed in April 2025.
What is SafeHeal's valuation?
SafeHeal's post-money valuation was not disclosed in connection with its Series C financing.
Who invested in SafeHeal?
The Series C was backed by Solar Eclipse, Sofinnova Partners, M&L Healthcare Investments, and Gideon Strategic Partners.
When was SafeHeal founded and where is it based?
SafeHeal was founded in 2015 and is headquartered in Paris, France.
Source: original announcement — read the full report.